Adjusted daily closes · 252 observations · as of Nov 6, 2026
Historical data, not a forecast
1 month
+17.1%
3 months
-11.6%
6 months
-10.7%
1 year
-3.6%
Year to date
-10.9%
52-week range
$153.01 – $229.98
Fundamental snapshot
Latest reported period: Sep 30, 2026
Sharadar reported data
Market cap
$5.89B
P/E
8.2
P/B
2.6
P/S
0.2
Revenue
$27.42B
Net income
$721.9M
Diluted EPS
20.79
Gross margin
17.70%
Net margin
2.60%
Return on equity
31.80%
Total debt
$7.35B
Cash
$51.2M
Free cash flow
$22.9M
Latest eight reported quarters
Reported quarterly values, newest first
Period
Revenue
Net income
Gross margin
Net margin
Free cash flow
Sep 30, 2026
$7.01B
$162.3M
17.20%
2.30%
$133.6M
Jun 30, 2026
$6.93B
$182.1M
17.80%
2.60%
-$140.7M
Mar 31, 2026
$6.55B
$205.4M
18.50%
3.10%
-$34.2M
Dec 31, 2025
$6.93B
$172.1M
17.50%
2.50%
$64.2M
Sep 30, 2025
$7.04B
$215.1M
17.60%
3.10%
$122.8M
Jun 30, 2025
$6.97B
$86.4M
18.30%
1.20%
-$256.8M
Mar 31, 2025
$6.69B
$175.5M
18.20%
2.60%
-$127.7M
Dec 31, 2024
$7.21B
$186.1M
17.20%
2.60%
$83.5M
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
Huntington Bancshares Inc. director James D. Rollins III reported gifting a total of 19,500 preferred-stock depositary shares across four series (H, L, I, and J) on November 4, 2026. Following these transactions, his direct holdings included shares from each gifted series, and he also held significant indirect shares of Series H and Series L through an LLC. The SEC Form 4 filing details these bona fide gifts and his remaining beneficial ownership.
Palo Alto Networks is reportedly in negotiations to acquire Beacon Security, a two-year-old Israeli cybersecurity startup. Beacon specializes in agentic security, developing a platform that enables AI agents to autonomously detect, investigate, and respond to cyber threats by consolidating and enriching data from various security systems. This potential acquisition aligns with Palo Alto Networks' strategy of expanding its technology portfolio through Israeli cybersecurity firms, having acquired 12 such startups since 2014.
AN2 Therapeutics, Inc. (NASDAQ: ANTX) announced that its Co-Founder, Chairman, President, and CEO, Eric Easom, will present at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026, at 9:30 am GMT. The company, a clinical stage biopharmaceutical firm, will also have management available for one-on-one meetings. A webcast of the presentation will be accessible on the Investors section of the AN2 Therapeutics website.
ANI Pharmaceuticals has made a public offer to acquire Egetis Therapeutics for approximately SEK 5.6 billion ($560 million). The acquisition aims to expand ANI's rare disease business by adding EMCITATE, an approved treatment for MCT8 deficiency, which ANI estimates could achieve peak sales of over $300 million with patent protection extending into mid-2045. Egetis's board unanimously recommends the offer, and shareholders representing about 42% of outstanding shares have committed to accept, with the deal contingent on 90% shareholder acceptance and regulatory approvals.
ANI Pharmaceuticals has announced a recommended public offer to acquire Egetis Therapeutics AB for approximately $560 million. This acquisition aims to expand ANI's rare disease business, leveraging Egetis's lead asset, EMCITATE®, an approved treatment for MCT8 deficiency with an estimated peak sales potential of over $300 million. The deal is unanimously recommended by Egetis's Board and supported by shareholders controlling 42% of its shares.
Information in Investor’s Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The...